<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6178028c-ef0f-4d64-b7bc-8b92d2d840ee"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)<br/>
         <br/>
      </content>
      <content styleCode="bold">(5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg)<br/>
         <br/>
      </content>
      <content styleCode="bold">CII<br/>
         <br/>
      </content>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20150430"/>
   <setId root="72ddd1c9-ddbd-4c95-acd9-003189a353a3"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="047021092" root="1.3.6.1.4.1.519.1"/>
            <name>Mallinckrodt, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ee779fcb-b30a-46dc-9b9d-76fec8b70420"/>
               <code code="48780-1" displayName="SPL LISTING DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20150601"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8891" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8891-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">5;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48350" displayName="SQUARE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8884" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.875"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.875"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.875"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.875"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8884-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">7;5;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48350" displayName="SQUARE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8892" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8892-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">10;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48350" displayName="SQUARE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8886" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8886-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">12;5;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48344" displayName="OCTAGON (8 SIDED)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8885" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8885-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">15;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48344" displayName="OCTAGON (8 SIDED)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8893" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8893-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">20;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48344" displayName="OCTAGON (8 SIDED)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0406-8894" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0406-8894-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040440" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to cream colored/mottled</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">30;M</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48344" displayName="OCTAGON (8 SIDED)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_90d89850-7980-4062-a89c-204e3b8bb901">
               <id root="e494c202-c13d-4f06-ad44-5573c227f7d4"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MISUSE OF AMPHETAMINE MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20150430"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d0235b76-8922-4153-a4c1-cb6545329f47">
               <id root="c44b87f5-da7b-4984-86c8-1d6f4189861d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>A single-entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate monohydrate. The structural formulas are as follows:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <table width="100%">
                     <col width="147.7pt"/>
                     <col width="49.5pt"/>
                     <col width="0.75in"/>
                     <col width="45.65pt"/>
                     <col width="65.65pt"/>
                     <col width="49.5pt"/>
                     <col width="0.75in"/>
                     <col width="74.45pt"/>
                     <tbody>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="bold">EACH TABLET </content>
                                 <content styleCode="bold">CONTAINS:</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">5 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">7.5 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">10 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">12.5 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">15 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">20 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="underline">30 mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Dextroamphetamine Saccharate</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.25 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.875 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>2.5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.125 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.75 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>7.5 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Amphetamine Aspartate Monohydrate</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.25 mg*</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.875 mg<sup>†</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>2.5 mg<sup>‡</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.125 mg<sup>§</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.75 mg<sup>¶</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>5 mg<sup>#</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>7.5 mg<sup>Þ</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Dextroamphetamine Sulfate USP</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.25 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.875 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>2.5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.125 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.75 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>7.5 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Amphetamine Sulfate USP</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.25 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>1.875 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>2.5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.125 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.75 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>5 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>7.5 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Total Amphetamine Base Equivalence</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>3.13 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>4.7 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>6.3 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>7.8 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>9.4 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>12.6 mg</paragraph>
                           </td>
                           <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>18.8 mg</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">*</content>1.25 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 1.17 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">†</content>1.875 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 1.755 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">‡</content>2.5 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 2.34 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">§</content>3.125 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 2.925 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">¶</content>3.75 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 3.51 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">#</content>5 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 4.6 mg Amphetamine Aspartate (Anhydrous) <br/>
                     <content styleCode="bold">Þ</content>7.5 mg of Amphetamine Aspartate Monohydrate as supplied equivalent to 7.03 mg Amphetamine Aspartate (Anhydrous) </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients<br/>
                     </content>Microcrystalline cellulose, silicon dioxide, povidone, and stearic acid.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Colors<br/>
                     </content>Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product) 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg are white to cream colored/mottled tablets, which contain no color additives. </paragraph>
               </text>
               <effectiveTime value="20150430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural Formulas</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1fda50fe-f349-485d-b3c7-d21c7c50c6eb">
               <id root="4bdd6e18-fccb-4c8a-bf20-84165b1f1bcc"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20150202"/>
               <component>
                  <section ID="LINK_e5680937-3797-4da3-a03d-52e2e0d3589e">
                     <id root="7b3fbd34-cde7-4820-bf29-71ca575d902d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>Pharmacodynamics</title>
                     <text>
                        <paragraph>Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known.  Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_69583f7b-7545-4ad2-8c73-6f084fa92a08">
                     <id root="8ae4f46e-ca90-4c19-b619-29eb8a3a58e0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>Mixed Salts of a Single Entity Amphetamine Product contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following administration of a single dose 10 or 30 mg of Mixed Salts of a Single Entity Amphetamine Product to healthy volunteers under fasted conditions, peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and l-amphetamine. The mean elimination half-life (t<sub>½</sub>) for d-amphetamine was shorter than the t<sub>½</sub> of the l-isomer (9.77 to 11 hours vs. 11.5 to 13.8 hours). The PK parameters (C<sub>max</sub>, AUC<sub>0-inf</sub>) of d- and l-amphetamine increased approximately three-fold from 10 mg to 30 mg indicating dose-proportional pharmacokinetics.  The effect of food on the bioavailability of Mixed Salts of a Single Entity Amphetamine Product has not been studied.  </paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b15020cc-e885-4c7a-8c09-7698caba97a7">
                     <id root="5ff2d6c2-da72-4b4d-a0de-f65220f4436a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Metabolism and Excretion</title>
                     <text>
                        <paragraph>Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form <br/>4-hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. <br/>Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility. </paragraph>
                        <paragraph>Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. <content styleCode="italics">In vitro </content>experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to <content styleCode="italics">in vivo </content>concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes <content styleCode="italics">in vivo </content>can be made. </paragraph>
                        <paragraph>With normal urine pHs approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30% to 40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that affect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamine’s metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased (<content styleCode="italics">see  </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_9be44d26-df77-421b-94f5-96b13e4893f6">PRECAUTIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e91a9adf-7aba-404f-a238-5a8e26431744">
               <id root="6fdf791d-5f71-4818-bdbc-0926c8a436b9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. </paragraph>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <section ID="LINK_ad6c8362-228c-48eb-ac00-66a9ea51b2b1">
                     <id root="91ad2c80-c539-477e-af33-1785fc10a45b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Attention Deficit Hyperactivity Disorder (ADHD)</title>
                     <text>
                        <paragraph>A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV<sup>®</sup>) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go;” excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                     <component>
                        <section ID="LINK_c4b38da5-5814-4a6a-8326-a696a6a91619">
                           <id root="891a878a-b92d-4322-a314-8cd263020826"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Special Diagnostic Considerations </content>
                                 <content styleCode="bold">–</content> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV<sup>® </sup>characteristics.  </paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_1b272572-da91-4965-8420-3c4a286d210e">
                           <id root="8cb06461-b387-4faf-8579-fac3b3a0511f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Need for Comprehensive Treatment Program </content>
                                 <content styleCode="bold">–</content> Mixed Salts of a Single Entity Amphetamine Product are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_1975b64a-49eb-4951-a4f2-fe51a20ce066">
                           <id root="6bd258e9-a3a6-428c-9ae0-9ba95d529530"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Long-Term Use </content>
                                 <content styleCode="bold">– </content>The effectiveness of Mixed Salts of a Single Entity Amphetamine Product for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Mixed Salts of a Single Entity Amphetamine Product for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. </paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3214b114-3fb0-49b5-8a24-94c3ab268e01">
               <id root="4d643f39-fa09-43a5-8376-111f0de24626"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.</paragraph>
                  <paragraph>Agitated states.</paragraph>
                  <paragraph>Patients with a history of drug abuse.</paragraph>
                  <paragraph>During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).</paragraph>
               </text>
               <effectiveTime value="20150202"/>
            </section>
         </component>
         <component>
            <section ID="LINK_cf6d5dd6-c455-40de-9288-0165efa2683b">
               <id root="319380b2-d71b-44cb-baa2-e9620a5c4885"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Serious Cardiovascular Events</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems</content>
                  </paragraph>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <section ID="LINK_51e78113-3602-477b-86e0-ab77ab1a4d54">
                     <id root="d468f407-1a0e-4693-81d5-8bb2ca321fa8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Children and Adolescents </content>
                           <content styleCode="bold">– </content> Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. </paragraph>
                        <paragraph>Although some structural heart problems alone may carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug (<content styleCode="italics">see </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_3214b114-3fb0-49b5-8a24-94c3ab268e01">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_df8db7d7-c713-4f50-a82b-6cb37de6a47c">
                     <id root="683c6973-1b07-48c7-807d-06d791eca381"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Adults </content>– Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (<content styleCode="italics">see </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_3214b114-3fb0-49b5-8a24-94c3ab268e01">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a225934e-97a1-4533-956c-a29fdecd7d70">
                     <id root="e3292d6e-bc73-4bf4-a331-f3fc9c5ba172"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypertension and Other Cardiovascular Conditions</title>
                     <text>
                        <paragraph>Stimulant medications cause a modest increase in average blood pressure (about 2 to 4 mmHg) and average heart rate (about 3 to 6 bpm) (<content styleCode="italics">see </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_580c154c-2e37-48e9-9358-2464b7af8f17">ADVERSE REACTIONS</linkHtml>
                           </content>), and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (<content styleCode="italics">see </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_3214b114-3fb0-49b5-8a24-94c3ab268e01">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7b8da73b-a0a1-48c3-a619-42963f98c03f">
                     <id root="63dfef34-5aef-47cc-b313-3367ed397ed6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</title>
                     <text>
                        <paragraph>Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5a2ee019-d85d-48bc-8e5d-6e866dc545ef">
                     <id root="f60ffe45-9c5a-418b-9e19-3a702a2296f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Psychiatric Adverse Events</title>
                     <effectiveTime value="20150202"/>
                     <component>
                        <section ID="LINK_e9bc065c-45d8-44fa-9240-6a1f42116a20">
                           <id root="005b878d-3d35-4d3d-8a84-5446fdcfdd4a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Pre-Existing Psychosis </content>– Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_863a73f6-4469-4c9a-9a28-61860e99c18c">
                           <id root="1d666ba7-cf8c-40fa-94e2-a79d2906dbcd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Bipolar Illness </content>– Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_19522401-0a58-4056-aa49-0d6de9aea62a">
                           <id root="d18a3403-247b-45e1-a856-46de3dc670e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Emergence of New Psychotic or Manic Symptoms </content>– Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_02d9a64a-ee3f-4f29-8dbc-718f4baad7a7">
                           <id root="02612cfe-601f-4d06-8cd0-2935a06933d7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Aggression </content>– Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6a7e7e42-c5bc-4a2b-b24e-f848b23e688e">
                     <id root="f19be8ab-1b7e-45de-82d9-4143b33e3947"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Long-Term Suppression of Growth</title>
                     <text>
                        <paragraph>Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they will likely have this effect as well.  Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_30b5837e-6f36-45c4-9b9c-9f088513918d">
                     <id root="ec507b95-e9b9-4e68-842b-9616c4c37b1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Seizures</title>
                     <text>
                        <paragraph>There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.  In the presence of seizures, the drug should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f1f06451-4dbf-4296-a97d-e34f74ff13d5">
                     <id root="ee9cede0-94f5-4eb2-a681-e2a16424e11b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Peripheral Vasculopathy, Including Raynaud’s Phenomenon</content>
                     </title>
                     <text>
                        <paragraph>Stimulants, including Mixed Salts of a Single Entity Amphetamine Product, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ae0a128c-733f-4817-8419-5d426d9b72bd">
                     <id root="e12098c6-e3e4-4f98-a550-7fa50f7d52d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Visual Disturbance</title>
                     <text>
                        <paragraph>Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9be44d26-df77-421b-94f5-96b13e4893f6">
               <id root="62633bfb-3a32-4929-918f-8c04027858c4"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20150430"/>
               <component>
                  <section ID="LINK_e7f8ebfd-cdc7-4282-84bb-2b43311f1f35">
                     <id root="c44b18ae-637b-4124-af23-ac5faaf31568"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Mixed Salts of a Single Entity Amphetamine Product should be used with caution in patients who use other sympathomimetic drugs.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9118f9ad-b336-4646-8a80-0a4c1a8b0e30">
                     <id root="2cda64ad-3a86-4e09-a76d-0be338824567"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Tics</title>
                     <text>
                        <paragraph>Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome.  Therefore, clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c2c656fb-fe44-4469-896c-ecc7f6b9cca9">
                     <id root="8d764cd9-46c8-441c-a939-0d797a467f82"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.</paragraph>
                        <paragraph>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with amphetamine or dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for Mixed Salts of a Single Entity Amphetamine Product.</paragraph>
                        <paragraph>The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</paragraph>
                        <paragraph>Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Instruct patients beginning treatment with Mixed Salts of a Single Entity Amphetamine Product about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</item>
                           <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</item>
                           <item>
                              <content styleCode="bold">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking Mixed Salts of a Single Entity Amphetamine Product.</content>
                           </item>
                           <item>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9c9e038f-9c2d-48ac-a345-0dae293cea8e">
                     <id root="26aea574-6a1d-4882-acd5-5fdd4d1fd894"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <effectiveTime value="20150430"/>
                     <component>
                        <section ID="LINK_b689eaad-8c5a-4f81-9ce8-6365e059abf8">
                           <id root="d7080465-4203-4567-8bc3-d6aec7774bcb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Acidifying Agents –</content> Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_55c00953-340d-48a8-ba14-3c9aab181d41">
                           <id root="23fd3771-632c-40e4-a2a9-852086528745"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Urinary Acidifying Agents –</content> (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_e6c6c736-2b44-40d4-ac78-989359780819">
                           <id root="c30b56dd-26a9-419b-be91-dacea9f1708a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Adrenergic Blockers –</content> Adrenergic blockers are inhibited by amphetamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_2afca889-a7de-4590-818d-25549f6305da">
                           <id root="fb2d37a2-0933-44b7-9d87-36fca4a75f91"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Alkalinizing Agents –</content> Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Co-administration of Mixed Salts of a Single Entity Amphetamine Product and gastrointestinal alkalizing agents, such as antacids, should be avoided.  Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_a5ea2246-fc07-49d5-970e-85c0f03a5621">
                           <id root="473f6bd0-cbbf-41bb-a056-d52c8fb485cb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Antidepressants, Tricyclic –</content> Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_098e7eca-b443-4534-8ae3-3d22fc8cff63">
                           <id root="9a8d96c9-b518-4152-a3cd-d45e1b2874f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">MAO Inhibitors –</content> MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ba855563-60da-49bf-bdb5-f01cf1602f8c">
                           <id root="f1ebcdd4-a3e2-4945-b04d-b17ca2528d66"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Antihistamines –</content> Amphetamines may counteract the sedative effect of antihistamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_fd4f21da-5b29-4b7f-ba76-c6ef87f94c41">
                           <id root="42a8882c-756c-46ef-b29e-0e02a6389ce2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Antihypertensives –</content> Amphetamines may antagonize the hypotensive effects of antihypertensives.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ec6c79d9-0842-4eb6-978a-269b0a63026b">
                           <id root="e415faf1-252a-4570-8185-d7fec1ec701e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Chlorpromazine –</content> Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_1c12257f-24a6-4d2f-bded-26fead25b1a3">
                           <id root="3a3c822b-f182-4978-a69b-a8f2fd975270"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Ethosuximide –</content> Amphetamines may delay intestinal absorption of ethosuximide.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_7c1c1cd8-a2e6-490b-bd44-7ab2496f17e3">
                           <id root="08025587-659c-4306-a3b4-24ebe4b6324a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Haloperidol –</content> Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_c42f19f9-7577-45e1-ac4e-1f6040c3bf8a">
                           <id root="84690231-8cc9-419d-8d40-66e7d40a6b8d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Lithium Carbonate –</content> The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_99b1a517-1b48-4edb-bc6b-b77d2a90b98c">
                           <id root="ee751cef-3bd7-444a-aa53-1260795e2414"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Meperidine –</content> Amphetamines potentiate the analgesic effect of meperidine.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_da69e8d1-039e-4045-ac1c-c55b1d10356f">
                           <id root="aab92470-b140-427c-8c2b-0f91a4b9156b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Methenamine Therapy –</content> Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_e10033e9-5ced-4179-af1c-a93a6e27a640">
                           <id root="cf200384-f451-4e1e-8b24-722ed98c7c5b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Norepinephrine </content>
                                 <content styleCode="bold">–</content> Amphetamines enhance the adrenergic effect of norepinephrine.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_dc1bd01f-c523-4c0d-bc98-e7f30f735b6a">
                           <id root="fa409bf9-3d5f-4195-afff-530507abc086"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Phenobarbital –</content> Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Phenytoin –</content> Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_3e1bf15a-12de-434d-b23c-053def40212d">
                           <id root="e786df28-0bd0-485b-a0d1-5a0543fed8a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Propoxyphene –</content> In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_babd0e14-4be2-471c-90a4-67b042711521">
                           <id root="d996b634-2456-46a3-b2d3-bb352517b1c3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Veratrum Alkaloids –</content> Amphetamines inhibit the hypotensive effect of veratrum alkaloids.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dd125bb9-297b-429c-a27e-4df6f1d3d08e">
                     <id root="047892b0-4aeb-4f98-82b4-9c817aecb81a"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_031ea8b1-b64f-4a52-8e70-eb5cd0bcbe03">
                     <id root="5015c0da-289d-4136-8a51-acd8295555ac"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis/Mutagenesis and Impairment of Fertility</title>
                     <text>
                        <paragraph>No evidence of carcinogenicity was found in studies in which d, l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<sup>2</sup> body surface area basis. </paragraph>
                        <paragraph>Amphetamine, in the enantiomer ratio present in Mixed Salts of a Single Entity Amphetamine Product (immediate-release)(d- to l- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test <content styleCode="italics">in vivo</content> and was negative when tested in the E. coli component of the Ames test <content styleCode="italics">in vitro</content>. d, l-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the <content styleCode="italics">in vitro</content> sister chromatid exchange and chromosomal aberration assays. </paragraph>
                        <paragraph>Amphetamine, in the enantiomer ratio present in Mixed Salts of a Single Entity Amphetamine Product (immediate-release)(d- to l- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2 </sup>body surface area basis). </paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9e592d7a-01f6-4b6c-a1f6-b9b715bc77aa">
                     <id root="3d5e60e1-aa08-4849-a86a-3f994f3a1356"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20150202"/>
                     <component>
                        <section ID="LINK_e0f76fb2-8bd2-4427-aba3-a38ab871e55e">
                           <id root="cb389c91-bfda-4bc3-a046-f56e41b9db7f"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Teratogenic Effects. </content>
                                 <content styleCode="italics">Pregnancy Category C – </content>Amphetamine, in the enantiomer ratio present in Mixed Salts of a Single Entity Amphetamine Product (d- to l- ratio of 3:1), had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and <br/>8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<sup>2</sup> body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times that of a human dose of 30 mg/day [child] on a mg/m<sup>2</sup> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity. </paragraph>
                              <paragraph>A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,l-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function. </paragraph>
                              <paragraph>There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_d820019f-380b-473d-b61b-4ee69f7353c7">
                           <id root="a1b34cfe-c841-4ce0-984a-60edbc630050"/>
                           <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Nonteratogenic Effects </content>– Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.</paragraph>
                           </text>
                           <effectiveTime value="20150202"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cea08dd8-e845-473f-8479-856f802ffc91">
                     <id root="17a691c1-ed99-479a-a11e-349663b13f48"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Usage in Nursing Mothers </content>– Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_76f7df82-1bc2-48bf-801a-4b1f9987e01d">
                     <id root="f696ed20-d611-4cb5-83b9-9be3d017ab23"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric Use </content>– Long-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age with Attention Deficit Hyperactivity Disorder described under <content styleCode="bold">
                              <linkHtml href="#LINK_e91a9adf-7aba-404f-a238-5a8e26431744">INDICATIONS AND USAGE</linkHtml>
                           </content>.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_953b9a02-8c3f-4461-979f-fc31a8bad2c2">
                     <id root="277b0254-41e7-48e1-baa1-19de237c1cc1"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Geriatric Use </content>– Mixed Salts of a Single Entity Amphetamine Product have not been studied in the geriatric population. </paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_580c154c-2e37-48e9-9358-2464b7af8f17">
               <id root="80a2fda8-36a7-4293-b9ad-508a14dd0328"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular </content>– Palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Central Nervous System – </content>Psychotic episodes at recommended doses, overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremor, tics, aggression, anger, logorrhea, dermatillomania.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Eye Disorders </content>
                     <content styleCode="bold">– </content>Vision blurred, mydriasis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal –</content> Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Allergic – </content>Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Endocrine – </content>Impotence, changes in libido, frequent or prolonged erections.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skin –</content> Alopecia.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Musculoskeletal –</content> Rhabdomyolysis. </paragraph>
               </text>
               <effectiveTime value="20150202"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fd015fc2-ec92-4498-887f-af1e5483f786">
               <id root="b53cbf40-1988-48f0-a72d-e7033e9531c2"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product is a Schedule II controlled substance.</paragraph>
                  <paragraph>Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. </paragraph>
               </text>
               <effectiveTime value="20150202"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c499eadc-005e-45ad-be83-a397fd641589">
               <id root="c0938a1d-1603-4fcf-af7b-3db7b3968ed6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses. </paragraph>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <section ID="LINK_36b427a7-8c20-436e-8127-7b586cb3f211">
                     <id root="12d36547-e351-4557-9c4f-387062aac06b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Symptoms</title>
                     <text>
                        <paragraph>Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. </paragraph>
                        <paragraph>Fatigue and depression usually follow the central stimulation.</paragraph>
                        <paragraph>Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. </paragraph>
                        <paragraph>Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_53a085e5-4034-405a-a876-abc784d3e5c1">
                     <id root="0591a818-bb50-4265-8530-6ef03072958b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Treatment</title>
                     <text>
                        <paragraph>Consult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine (Regitine<sup>™</sup>) has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_22eede3b-8b56-4d5d-8ace-514899b98890">
               <id root="25dd5ce6-f4b7-491b-8e27-b38ffe69d559"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Regardless of indication, amphetamines should be administered at the lowest effective dosage, and dosage should be individually adjusted according to the therapeutic needs and response of the patient. Late evening doses should be avoided because of the resulting insomnia. </paragraph>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <section ID="LINK_46a08020-c5ed-4d0e-92ec-202b91102994">
                     <id root="253186d5-d036-472a-9079-3dee01aea303"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Attention Deficit Hyperactivity Disorder</title>
                     <text>
                        <paragraph>Not recommended for children under 3 years of age. In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.</paragraph>
                        <paragraph>In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours. </paragraph>
                        <paragraph>Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2626735f-561d-4b49-9f48-29ab2a3d47d7">
                     <id root="4056d37d-ad15-4166-a7c1-cb3262dc9e89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Narcolepsy</title>
                     <text>
                        <paragraph>Usual dose 5 mg to 60 mg per day in divided doses, depending on the individual patient response.</paragraph>
                        <paragraph>Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.</paragraph>
                     </text>
                     <effectiveTime value="20150202"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d40d050a-3044-4b45-a9ca-5b0bc5ea6593">
               <id root="d53896ac-da08-491a-bec6-f9302f0d95f9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product) are supplied as follows: </paragraph>
                  <paragraph>5 mg: White to cream colored/mottled pillow shaped tablet, debossed with a “5” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM2"/> on the other side.  Bottles of 100….NDC 0406-8891-01</paragraph>
                  <paragraph> 7.5 mg:  White to cream colored/mottled pillow shaped tablet, debossed with a “7.5” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM3"/> on the other side.  Bottles of 100….NDC 0406-8884-01 </paragraph>
                  <paragraph>10 mg:  White to cream colored/mottled pillow shaped tablet, debossed with a “10” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM4"/> on the other side.<br/>Bottles of 100….NDC 0406-8892-01</paragraph>
                  <paragraph>12.5 mg:  White to cream colored/mottled octagon shaped tablet, debossed with a “12.5” and a partial quadrisect on one side and a  <renderMultiMedia referencedObject="MM5"/> on the other side.  Bottles of 100….NDC 0406-8886-01 </paragraph>
                  <paragraph>15 mg:  White to cream colored/mottled octagon shaped tablet, debossed with a “15” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM6"/> on the other side.  Bottles of 100….NDC 0406-8885-01 </paragraph>
                  <paragraph>20 mg:  White to cream colored/mottled octagon shaped tablet, debossed with a “20” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM7"/> on the other side.  Bottles of 100….NDC 0406-8893-01</paragraph>
                  <paragraph>30 mg:  White to cream colored/mottled octagon shaped tablet, debossed with a “30” and a partial quadrisect on one side and a <renderMultiMedia referencedObject="MM8"/> on the other side.  Bottles of 100….NDC 0406-8894-01</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt, the “M” brand mark, the Mallinckrodt Pharmaceuticals logo and <renderMultiMedia referencedObject="MM9"/> are trademarks of a Mallinckrodt company.</paragraph>
                  <paragraph>© 2015 Mallinckrodt. </paragraph>
                  <paragraph>Regitine is a trademark of its respective owner. </paragraph>
                  <paragraph>Mallinckrodt Inc. <br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>Rev 04/2015    </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mallinckrodt™<br/>
                     </content>Pharmaceuticals    </paragraph>
               </text>
               <effectiveTime value="20150430"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Mallinckrodt</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>M</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_158ba085-9642-4cee-953d-714f559c1ba1">
               <id root="3a7d5319-fa91-4eeb-b80c-69b704ad0d86"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>Read the Medication Guide that comes with Mixed Salts of a Single Entity Amphetamine Product before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your or your child’s treatment with Mixed Salts of a Single Entity Amphetamine Product. </paragraph>
                  <table>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about Mixed Salts of a Single Entity Amphetamine Product? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">The following have been reported with use of Mixed Salts of a Single Entity Amphetamine Product and other stimulant medicines. </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">1. Heart-Related Problems: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">sudden death in patients who have heart problems or heart defects </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">stroke and heart attack in adults </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">increased blood pressure and heart rate </content>
                                 </item>
                              </list>
                              <paragraph>Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. </paragraph>
                              <paragraph>Your doctor should check you or your child carefully for heart problems before starting Mixed Salts of a Single Entity Amphetamine Product.</paragraph>
                              <paragraph>Your doctor should check your or your child’s blood pressure and heart rate regularly during treatment with Mixed Salts of a Single Entity Amphetamine Product. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Mixed Salts of a Single Entity Amphetamine Product.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">2. Mental (Psychiatric) Problems: </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">All Patients </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">new or worse behavior and thought problems </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">new or worse bipolar illness </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">new or worse aggressive behavior or hostility </content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Children and Teenagers </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms </content>
                                 </item>
                              </list>
                              <paragraph>Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking Mixed Salts of a Single Entity Amphetamine Product, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious. </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">3. Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Fingers or toes may feel numb, cool, painful</item>
                                 <item>Fingers or toes may change color from pale, to blue, to red</item>
                              </list>
                              <paragraph>Tell your doctor if you have or your child has numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor right away if you have or your child has any signs of unexplained wounds appearing on fingers or toes while taking Mixed Salts of a Single Entity Amphetamine Product.</content> </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What are Mixed Salts of a Single Entity Amphetamine Product? </content>
                  </paragraph>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product are a central nervous system stimulant prescription medicine. <content styleCode="bold">They are used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</content> Mixed Salts of a Single Entity Amphetamine Product may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD. </paragraph>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product should be used as a part of a total treatment program for ADHD that may include counseling or other therapies. </paragraph>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product are also used in the treatment of a sleep disorder called narcolepsy. </paragraph>
                  <table>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <content styleCode="bold">Mixed Salts of a Single Entity Amphetamine Product are a federally controlled substance (CII) because they can be abused or lead to dependence. Keep Mixed Salts of a Single Entity Amphetamine Product in a safe place to prevent misuse and abuse. Selling or giving away Mixed Salts of a Single Entity Amphetamine Product may harm others, and is against the law. </content>
                              <paragraph>Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs. </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Who should not take Mixed Salts of a Single Entity Amphetamine Product?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mixed Salts of a Single Entity Amphetamine Product should not be taken if you or your child: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>have heart disease or hardening of the arteries </item>
                     <item>have moderate to severe high blood pressure </item>
                     <item>have hyperthyroidism </item>
                     <item>have an eye problem called glaucoma </item>
                     <item>are very anxious, tense, or agitated </item>
                     <item>have a history of drug abuse </item>
                     <item>are taking or have taken within the past 14 days an antidepression medicine called a monoamine oxidase inhibitor or MAOI</item>
                     <item>are sensitive to, allergic to, or had a reaction to other stimulant medicines </item>
                  </list>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product are not recommended for use in children less than 3 years old. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mixed Salts of a Single Entity Amphetamine Product may not be right for you or your child. Before starting Mixed Salts of a Single Entity Amphetamine Product tell your or your child’s doctor about all health conditions (or a family history of) including: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>heart problems, heart defects, high blood pressure </item>
                     <item>mental problems including psychosis, mania, bipolar illness, or depression </item>
                     <item>tics or Tourette’s syndrome</item>
                     <item>liver or kidney problems</item>
                     <item>circulation problems in fingers and toes</item>
                     <item>thyroid problems </item>
                     <item>seizures or have had an abnormal brain wave test (EEG) </item>
                  </list>
                  <paragraph>Tell your doctor if you or your child are pregnant, planning to become pregnant, or breastfeeding. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Can Mixed Salts of a Single Entity Amphetamine Product be taken with other medicines? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor about all of the medicines that you or your child take including prescription and nonprescription medicines, vitamins, and herbal supplements. </content>Mixed Salts of a Single Entity Amphetamine Product and some medicines may interact with each other and cause serious side effects. </paragraph>
                  <paragraph>Sometimes the doses of other medicines will need to be adjusted while taking Mixed Salts of a Single Entity Amphetamine Product. </paragraph>
                  <paragraph>Your doctor will decide whether Mixed Salts of a Single Entity Amphetamine Product can be taken with other medicines. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Especially tell your doctor if you or your child take: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>antidepression medicines including MAOIs </item>
                     <item>blood pressure medicines </item>
                     <item>seizure medicines </item>
                     <item>blood thinner medicines</item>
                     <item>cold or allergy medicines that contain decongestants</item>
                     <item>stomach acid medicines</item>
                  </list>
                  <paragraph>Know the medicines that you or your child take. Keep a list of your medicines with you to show your doctor and pharmacist. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not start any new medicine while taking Mixed Salts of a Single Entity Amphetamine Product without talking to your doctor first. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should Mixed Salts of a Single Entity Amphetamine Product be taken? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Take Mixed Salts of a Single Entity Amphetamine Product exactly as prescribed.</content> Your doctor may adjust the dose until it is right for you or your child. </item>
                     <item>Mixed Salts of a Single Entity Amphetamine Product are usually taken two to three times a day. The first dose is usually taken when you first wake in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.</item>
                     <item>Mixed Salts of a Single Entity Amphetamine Product can be taken with or without food.</item>
                     <item>From time to time, your doctor may stop Mixed Salts of a Single Entity Amphetamine Product treatment for a while to check ADHD symptoms. </item>
                     <item>Your doctor may do regular checks of the blood, heart, and blood pressure while taking Mixed Salts of a Single Entity Amphetamine Product. Children should have their height and weight checked often while taking Mixed Salts of a Single Entity Amphetamine Product. Mixed Salts of a Single Entity Amphetamine Product treatment may be stopped if a problem is found during these check-ups. </item>
                     <item>
                        <content styleCode="bold">If you or your child take too much Mixed Salts of a Single Entity Amphetamine Product or overdoses, call your doctor or poison control center right away, or get emergency treatment. </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are possible side effects of Mixed Salts of a Single Entity Amphetamine Product? </content>
                  </paragraph>
                  <paragraph>See<content styleCode="bold"> “What is the most important information I should know about Mixed Salts of a Single Entity Amphetamine Product?”</content> for information on reported heart and mental problems. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>slowing of growth (height and weight) in children </item>
                     <item>seizures, mainly in patients with a history of seizures </item>
                     <item>eyesight changes or blurred vision </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Common side effects include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>headache</item>
                     <item>stomach ache</item>
                     <item>trouble sleeping</item>
                     <item>decreased appetite</item>
                     <item>nervousness</item>
                     <item>dizziness</item>
                  </list>
                  <paragraph>Mixed Salts of a Single Entity Amphetamine Product may affect your or your child’s ability to drive or do other dangerous activities. </paragraph>
                  <paragraph>Talk to your doctor if you or your child have side effects that are bothersome or do not go away. </paragraph>
                  <paragraph>This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information. </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store Mixed Salts of a Single Entity Amphetamine Product?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Store Mixed Salts of a Single Entity Amphetamine Product in a safe place at room temperature, 20º to 25ºC (68º to 77ºF).</item>
                     <item>
                        <content styleCode="bold">Keep Mixed Salts of a Single Entity Amphetamine Product and all medicines out of the reach of children. </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General information about Mixed Salts of a Single Entity Amphetamine Product</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Mixed Salts of a Single Entity Amphetamine Product for a condition for which they were not prescribed. Do not give Mixed Salts of a Single Entity Amphetamine Product to other people, even if they have the same condition. It may harm them and it is against the law. This Medication Guide summarizes the most important information about Mixed Salts of a Single Entity Amphetamine Product. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Mixed Salts of a Single Entity Amphetamine Product that was written for healthcare professionals, or you can visit <linkHtml href="#www.Mallinckrodt.com">www.Mallinckrodt.com</linkHtml> or call 1-800-778-7898.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Mixed Salts of a Single Entity Amphetamine Product? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredients: </content>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate USP and amphetamine sulfate USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients: </content>microcrystalline cellulose, silicon dioxide, povidone and stearic acid</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.</paragraph>
                  <paragraph>© 2015 Mallinckrodt.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>Rev 04/2015         </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mallinckrodt™</content>
                     <br/>Pharmaceuticals</paragraph>
               </text>
               <effectiveTime value="20150430"/>
            </section>
         </component>
         <component>
            <section ID="LINK_744b7ad6-79ce-42ee-bc15-7ed717b60f05">
               <id root="491cff5c-cfcd-4b34-bdb8-2a0f6776c496"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg</title>
               <text>
                  <paragraph>NDC 0406-8891-01                        <content styleCode="bold">100 TABLETS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">5 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate, 1.25 mg; Amphetamine Aspartate Monohydrate, 1.25 mg (Equivalent to 1.17 mg amphetamine aspartate); Dextroamphetamine Sulfate USP, 1.25 mg; Amphetamine Sulfate USP, 1.25 mg; (Total amphetamine base equivalence 3.13  mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D55                    Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL - 5 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c945780c-8581-467c-9f47-c18de0330f7f">
               <id root="3319a945-04ce-4343-b022-65b2c78a1879"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 7.5 mg</title>
               <text>
                  <paragraph>NDC 0406-8884-01                        <content styleCode="bold">100 TABLETS<br/>
                     </content>
                  </paragraph>
                  <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">7.5 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate, 1.875 mg; Amphetamine Aspartate Monohydrate, 1.875 mg; (Equivalent to 1.755 mg amphetamine aspartate); Dextroamphetamine Sulfate USP, 1.875 mg;Amphetamine Sulfate USP, 1.875 mg (Total amphetamine base equivalence 4.7 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D58                     Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PRINCIPAL DISPLAY PANEL - 7.5 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_80d9e828-efab-43f6-9764-5f5a27b36eb4">
               <id root="fd8a167b-530c-4436-adab-afae4f568ee5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mg</title>
               <text>
                  <paragraph>NDC 0406-8892-01                        <content styleCode="bold">100 TABLETS<br/>
                     </content>
                  </paragraph>
                  <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">10 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate,  2.5 mg;Amphetamine Aspartate Monohydrate, 2.5 mg<br/>(Equivalent to 2.34 mg amphetamine aspartate);Dextroamphetamine Sulfate USP, 2.5 mg<br/>Amphetamine Sulfate USP, 2.5 mg (Total amphetamine base equivalence 6.3 mg)<br/>
                     <br/>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D61                    Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>PRINCIPAL DISPLAY PANEL - 10 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cdd7cfb6-4322-45c0-9131-235b9df2ac42">
               <id root="b4920f2a-79ef-4f66-85f8-7b7a2859e114"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 12.5 mg</title>
               <text>
                  <paragraph>NDC 0406-8886-01                       <content styleCode="bold"> 100 TABLETS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">12.5 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate,  3.125 mg; Amphetamine Aspartate Monohydrate, 3.125 mg (Equivalent to 2.925 mg amphetamine aspartate); Dextroamphetamine Sulfate USP, 3.125 mg; Amphetamine Sulfate USP, 3.125 mg (Total amphetamine base equivalence 7.8 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D64                   Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM13"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>PRINCIPAL DISPLAY PANEL - 12.5 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bcf8c8cc-42fa-4c71-8c0b-43ff40580770">
               <id root="ab17a20d-1de8-416f-abbe-2921c3a82984"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 15 mg</title>
               <text>
                  <paragraph>NDC 0406-8885-01                        <content styleCode="bold">100 TABLETS<br/>
                     </content>
                  </paragraph>
                  <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">15 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate, 3.75 mg; Amphetamine Aspartate Monohydrate, 3.75 mg (Equivalent to 3.51 mg amphetamine aspartate); <br/>Dextroamphetamine Sulfate USP, 3.75 mg; Amphetamine Sulfate USP, 3.75 mg (Total amphetamine base equivalence 9.4 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D67                     Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM14"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>PRINCIPAL DISPLAY PANEL - 15 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_865f2fb6-5632-403d-98ba-3ba1b47e9bcb">
               <id root="9afc5b99-70f9-4282-a6da-fa4ed5fcc761"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 20 mg</title>
               <text>
                  <paragraph>NDC 0406-8893-01                        <content styleCode="bold">100 TABLETS<br/>
                     </content>
                  </paragraph>
                  <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">20 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate, 5 mg; Amphetamine Aspartate Monohydrate, 5 mg (Equivalent to 4.6 mg amphetamine aspartate); Dextroamphetamine Sulfate USP, 5 mg; Amphetamine Sulfate USP, 5 mg; (Total amphetamine base equivalence 12.6 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D70                     Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM15"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM15">
                     <text>PRINCIPAL DISPLAY PANEL - 20 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_6744edd8-45d6-4b02-9e83-9a27850d40fc">
               <id root="34717451-cfb0-42a8-adb4-6095f1ab83d0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mg</title>
               <text>
                  <paragraph>NDC 0406-8894-01                        <content styleCode="bold">100 TABLETS<br/>
                     </content>
                  </paragraph>
                  <content styleCode="bold">Dextroamphetamine Saccharate<br/>Amphetamine Aspartate<br/>Dextroamphetamine Sulfate<br/>Amphetamine Sulfate Tablets<br/>(Mixed Salts of a Single Entity Amphetamine Product)</content>
                  <paragraph>
                     <content styleCode="bold">CII    </content>        <br/>
                     <content styleCode="bold">30 mg                    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>PHARMACIST: Dispense the Medication Guide provided seperately to each patient.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Mallinckrodt™</content>
                     </content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Dextroamphetamine Saccharate, 7.5 mg; Amphetamine Aspartate Monohydrate, 7.5 mg (Equivalent to 7.03 mg amphetamine aspartate);<br/>Dextroamphetamine Sulfate USP, 7.5 mg; Amphetamine Sulfate USP, 7.5 mg; (Total amphetamine base equivalence 18.8 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>  See package insert.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Mallinckrodt Inc.<br/>Hazelwood, MO 63042 USA</paragraph>
                  <paragraph>L00D73                   Rev. 11/2014</paragraph>
                  <renderMultiMedia referencedObject="MM16"/>
               </text>
               <effectiveTime value="20150202"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mixed-salts-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>